- Home
- ASTC vs TOVX Comparison
ASTC vs TOVX Comparison
Compare ASTC & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTC | TOVX |
|---|---|---|
| Founded | 1984 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1M | 6.4M |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | ASTC | TOVX |
|---|---|---|
| Price | $2.41 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.7K | ★ 5.8M |
| Earning Date | 05-29-2026 | 06-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2600.00 | 89.07 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.24 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.31 | $0.16 |
| 52 Week High | $8.01 | $1.50 |
Technical Indicators
Market Signals| Indicator | ASTC | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 22.97 | 41.68 |
| Support Level | N/A | $0.17 |
| Resistance Level | $2.92 | $0.26 |
| Average True Range (ATR) | 0.10 | 0.01 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 0.00 | 3.91 |
Price Performance
Historical ComparisonAbout ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.